Resveratrol for Exudative Age-Related Macular Degeneration (AGED)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02625376 |
Recruitment Status :
Terminated
First Posted : December 9, 2015
Last Update Posted : June 1, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
AMD Age-related Macular Degeneration Choroidal Neovascularisation | Dietary Supplement: Resvega Dietary Supplement: Trans-Resveratrol Dietary Supplement: placebo | Not Applicable |
Interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of Resveratrol to reduce the progression of exudative Age-Related Macular Degeneration.
Comparison of incidence of choroidal neaovascularization between each study group will be performed.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 25 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Prevention |
Official Title: | Influence of Resveratrol and Resvega Versus Placebo on Incidence of Bilateralisation of Exudative AMD: a Double Masked Prospective Study. |
Actual Study Start Date : | August 6, 2015 |
Actual Primary Completion Date : | October 26, 2016 |
Actual Study Completion Date : | November 9, 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: Trans-Resveratrol
capsule of 250 mg of resveratrol. two capsules daily : one in the morning and evening for 24 months
|
Dietary Supplement: Trans-Resveratrol
Dietary supplementation with resveratrol 250 mg BD |
Active Comparator: Resvega
capsule composed of antioxydant, omega 3, carotenoid, 15 mg of resveratrol, zinc and copper. two capsules daily : one in the morning and evening for 24 months |
Dietary Supplement: Resvega
Dietary supplementation with Resvega BD |
Placebo Comparator: Placebo
capsule of medium chain triglyceride. two capsules daily : one in the morning and evening for 24 months
|
Dietary Supplement: placebo
Dietary supplementation with a placebo BD |
- Comparaison of incidence of choroidal neovascularization between resveratrol group and placebo group at 24 months [ Time Frame: 24 months ]What is the influence of the daily intake of 500 mg of resveratrol on the incidence of neovascularization of the second eye?
- Comparaison of incidence of choroidal neovascularization between Resvega group and placebo group at 24 months [ Time Frame: 24 months ]What is the influence of the daily intake resvega on the incidence of neovascularization of the second eye?

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 55 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Men or women aged 55 or more with unilateral exudative AMD
- Visual acuity less or equal to 20/25 in the most affected eye
Exclusion Criteria:
- Allergy to an investigational product
- atrophic Age-Related Macular Degeneration or age related maculopathy
- significant media opacities
- Other retinal pathology (diabetic retinopathy, high myopia, retinal dystrophy)
- Recent Cataract surgery
- Previous history of vitrectomy
- Acute or chronic severe organ failure
- Present participation in other clinical research study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02625376
France | |
CHU de Poitiers - Ophtalmology | |
Poitiers, France, 86000 |
Principal Investigator: | Nicolas LEVEZIEL, MD, PhD | Dpt of Ophthalmology, University Hospital of Poitiers, France |
Responsible Party: | Poitiers University Hospital |
ClinicalTrials.gov Identifier: | NCT02625376 |
Other Study ID Numbers: |
AGED/EudraCT : 2015-001577-41 |
First Posted: | December 9, 2015 Key Record Dates |
Last Update Posted: | June 1, 2020 |
Last Verified: | May 2020 |
Macular Degeneration Choroidal Neovascularization Neovascularization, Pathologic Retinal Degeneration Retinal Diseases Eye Diseases Metaplasia Pathologic Processes Choroid Diseases Uveal Diseases Resveratrol Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics |
Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Antineoplastic Agents, Phytogenic Antineoplastic Agents Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Enzyme Inhibitors Platelet Aggregation Inhibitors Antimutagenic Agents Anticarcinogenic Agents |